Association of 5 alpha-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea

Abstract

IMPORTANCE The antiandrogenic effect of the 5a-reductase inhibitor (5-ARI) has been investigated for its role in preventing male-predominant cancers. Although 5-ARI has been widely associated with prostate cancer, its association with urothelial bladder cancer (BC), another cancer experienced predominantly by males, has been less explored. OBJECTIVE To assess the association between 5-ARI prescription prior to BC diagnosis and reduced risk of BC progression. DESIGN, SETTING, AND PARTICIPANTS This cohort study analyzed patient claims data from the Korean National Health Insurance Service database. The nationwide cohort included all male patients with BC diagnosis in this database from January 1, 2008, to December 31, 2019. Propensity score matching was conducted to balance the covariates between 2 treatment groups: a-blocker only group and 5-ARI plus a-blocker group. Data were analyzed from April 2021 to March 2023. EXPOSURE Newly dispensed prescriptions of 5-ARIs at least 12 months prior to cohort entry (BC diagnosis), with a minimum of 2 prescriptions filled. MAIN OUTCOMES AND MEASURES The primary outcomes were the risks of bladder instillation and radical cystectomy, and the secondary outcome was all-cause mortality. To compare the risk of outcomes, the hazard ratio (HR) was estimated using a Cox proportional hazards regression model and difference in restricted mean survival time analysis. RESULTS The study cohort initially included 22 845 males with BC. After propensity score matching, 5300 patients eachwere assigned to the a-blocker only group (mean [SD] age, 68.3 [8.8] years) and 5-ARI plus a-blocker group (mean [SD] age, 67.8 [8.6] years). Compared with the a-blocker only group, the 5-ARI plus a-blocker group had a lower risk of mortality (adjusted HR [AHR], 0.83; 95% CI, 0.75-0.91), bladder instillation (crude HR, 0.84; 95% CI, 0.77-0.92), and radical cystectomy (AHR, 0.74; 95% CI, 0.62-0.88). The differences in restricted mean survival time were 92.6 (95% CI, 25.7159.4) days for all-cause mortality, 88.1 (95% CI, 25.2-150.9) days for bladder instillation, and 68.0 (95% CI, 31.6-104.3) days for radical cystectomy. The incidence rates per 1000 person-years were 85.59 (95% CI, 80.53-90.88) for bladder instillation and 19.57 (95% CI, 17.41-21.91) for radical cystectomy in the a-blocker only group and 66.43 (95% CI, 62.22-70.84) for bladder instillation and 13.56 (95% CI, 11.86-15.45) for radical cystectomy in the 5-ARI plus a-blocker group. CONCLUSIONS AND RELEVANCE Results of this study suggest an association between prediagnostic prescription of 5-ARI and reduced risk of BC progression.